NCT04532957 is a Phase 1 clinical trial of KBP-7072 in Healthy, sponsored by KBP Biosciences.

Who is sponsoring NCT04532957?

NCT04532957 is sponsored by KBP Biosciences.

What drugs are being tested in NCT04532957?

Interventions in NCT04532957: KBP-7072, Placebo.

Is NCT04532957 still recruiting?

NCT04532957 is currently completed. Last updated 23 February 2024.

Last reviewed 2024-02-23 · How we verify

NCT04532957

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects

Completed Phase 1 Last updated 23 February 2024

What this trial tests

Phase 1 trial testing KBP-7072 in Healthy in 24 participants. Completed in 15 October 2020.

Timeline

11 August 2020

Primary endpoint
8 October 2020

15 October 2020

Quick facts

Lead sponsor	KBP Biosciences
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	24
Start date	11 August 2020
Primary completion	8 October 2020
Estimated completion	15 October 2020
Sites	1 location across United States

Drugs / interventions tested

KBP-7072 — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

KBP Biosciences — full company profile →

Who can join

Adults 18 to 50, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a double-blind, placebo-controlled, multiple oral dose study to evaluate safety, tolerability, and pharmacokinetic of KBP-7072 in healthy subjects.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.
Miller WR, Arias CA. · · 2024 · cited 481× · PMID 38831030 · DOI 10.1038/s41579-024-01054-w
Antibiotics in the clinical pipeline as of December 2022.
Butler MS, Henderson IR, Capon RJ, Blaskovich MAT. · · 2023 · cited 147× · PMID 37291465 · DOI 10.1038/s41429-023-00629-8
Unveiling the Secrets of <i>Acinetobacter baumannii</i>: Resistance, Current Treatments, and Future Innovations.
Marino A, Augello E, Stracquadanio S, Bellanca CM, et al · · 2024 · cited 44× · PMID 38999924 · DOI 10.3390/ijms25136814
Novel drug candidates against antibiotic-resistant microorganisms: A review.
Lim JS, Chai YY, Ser WX, Haeren AV, et al · · 2024 · cited 14× · PMID 38234674 · DOI 10.22038/ijbms.2023.71672.15593
Antibacterials with Novel Chemical Scaffolds in Clinical Development.
Heimann D, Kohnhäuser D, Kohnhäuser AJ, Brönstrup M. · · 2025 · cited 10× · PMID 39847315 · DOI 10.1007/s40265-024-02137-x

Verify or expand the search:

Other trials of KBP-7072

Trials testing the same drug.

NCT05507463 — Study of KBP-7072 in Healthy Male and Female Subjects · Phase 1 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other KBP Biosciences trials

Trials by the same sponsor.

NCT05507463 — Study of KBP-7072 in Healthy Male and Female Subjects · Phase 1 · completed
NCT04968184 — Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD) · Phase 3 · terminated
NCT04634812 — Mass Balance Study of KBP-5074 in Healthy Male Subjects · Phase 1 · completed
NCT04606537 — Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects · Phase 1 · completed
NCT04534699 — Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04532957 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by KBP Biosciences
Last refreshed: 23 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04532957.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing